Case report: A 9-year systematic treatment failure of a pulmonary tuberculosis patient

Front Public Health. 2022 Sep 6:10:966891. doi: 10.3389/fpubh.2022.966891. eCollection 2022.

Abstract

Objective: To explore the reasons of failure in a case of pulmonary tuberculosis (PTB) after 9 years systematic treatment.

Methods: We extracted the patients' treatment history, drug susceptibility testing (DST), Computed tomography (CT) images, and sequenced the isolated strains by whole gene sequencing (WGS).

Results: Although most results of the phenotypical DSTs were consistent with the genotype DST, the occurrence of gene resistance to amikacin (AMK), capreomycin (CAP), moxifloxacin (MFX) was earlier than the phenotypical DST. Based on the continuously reversed results of phenotypical DSTs, CT images in different stages and WGS, it can be confirmed that the patient was infected with two different strains of Mycobacterium tuberculosis (M.TB). Moreover, severe cavities may be another factor leading to treatment failure.

Conclusion: Given the suggestive effect of genotype DST is earlier than the phenotypical DST, so genotype DST can play a better guiding role in patients with MDR-TB. Additionally, for patients who have not been cured for a long time, medication should be more cautious and the role of WGS in drug resistance surveillance should be fully utilized.

Keywords: computed tomography-three dimensional; multidrug resistance; treatment failure; tuberculosis; whole genome sequencing.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amikacin / pharmacology
  • Amikacin / therapeutic use
  • Antitubercular Agents / pharmacology
  • Antitubercular Agents / therapeutic use
  • Capreomycin / pharmacology
  • Capreomycin / therapeutic use
  • Drug Resistance, Multiple, Bacterial / genetics
  • Humans
  • Microbial Sensitivity Tests
  • Moxifloxacin / pharmacology
  • Moxifloxacin / therapeutic use
  • Mycobacterium tuberculosis* / genetics
  • Treatment Failure
  • Tuberculosis, Pulmonary* / drug therapy

Substances

  • Antitubercular Agents
  • Capreomycin
  • Amikacin
  • Moxifloxacin